Sigachi Industries Limited is all set to begin operations at its brand-new Research & Development (R&D) Center in Hyderabad on July 28, 2025. The move marks a major step in the company’s plan to boost its innovation pipeline, especially in the area of high-value Active Pharmaceutical Ingredients (APIs) aimed at global markets.
Known for its strong presence in pharmaceutical excipients, APIs, and specialty ingredients, Sigachi aims to strengthen its technical and scientific edge through this new facility. The Hyderabad R&D Center will focus on end-to-end development of APIs—from early-stage lab research to commercialization and international regulatory submissions.
The R&D Center will house a team of 32–35 experienced scientists working to speed up product development with a focus on quality-by-design (QbD) principles and regulatory readiness. Sigachi sees this initiative as a key pillar in its long-term innovation strategy for regulated markets worldwide.
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, stated, “By investing in end-to-end R&D capabilities and consolidating API development and analytical functions under one roof, we are not just strengthening our backward integration — we are laying the foundation for Sigachi to emerge as a high-quality, globally competitive supplier in regulated pharmaceutical markets.”
